ArticleInternational journal of clinical oncology2025
Prognostic factors and the impact of neoadjuvant chemotherapy on the development of metastasis in patients with undifferentiated pleomorphic sarcoma of soft tissue.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Is the Thickness of the Margin Associated with Local Recurrence and Survival in Patients with Undifferentiated Pleomorphic Sarcoma?Medicina (Kaunas, Lithuania) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough undifferentiated pleomorphic sarcoma (UPS), previously termed as malignant fibrous histiocytoma (MFH), is one of the most common soft tissue sarcomas, the number of studies focusing on UPS remains limited. This retrospective study aimed to identify prognostic factors and assess the clinical impact of chemotherapy on the development of metastasis in patients with UPS.
methodsThis study included 147 patients with UPS who underwent tumor resection. The associations of various parameters with oncological outcomes were investigated. Furthermore, the efficacy of chemotherapy against the development of metastatic disease has been investigated in patients with localized UPS.
results5-year disease-specific and local recurrence-free survival rates were 71.7% and 61.6%, respectively. Metastatic disease at diagnosis (hazard ratio [HR], 16.7; P < 0.001) and trunk involvement (HR, 2.6; P = 0.015) were independently associated with disease-specific survival. R1/R2 resection (HR, 2.3; P = 0.008) and metastatic disease at diagnosis (HR, 5.2; P = 0.003) were independently associated with local recurrence-free survival. Among 39 patients who underwent neoadjuvant chemotherapy, 10 (25.6%) showed a good response (tumor necrosis ≥ 90%) to the neoadjuvant chemotherapy, and the responders showed a significantly higher metastasis-free survival rate than non-responders (P = 0.034).
conclusionsThis study showed that metastatic disease at diagnosis, trunk involvement, and incomplete resection are risk factors for poor oncological outcomes in patients with UPS, and that effective neoadjuvant chemotherapy decreases metastatic disease. The development of effective anticancer agents and methods for predicting of the chemotherapeutic effects is warranted to improve the clinical outcomes in patients with UPS.
Indexed as
Identifiers
40498277What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.